NCT01033981View on ClinicalTrials.gov

Cost Effectiveness Of Sunitinib In Central America And Caribbean

TerminatedOBSERVATIONAL

Enrollment

4

Participants

Timeline

Start Date

May 31, 2010

Primary Completion Date

February 28, 2011

Study Completion Date

February 28, 2011

Conditions

Metastatic Renal Cell Carcinoma

Interventions

DRUG

Sunitinib

Treatment for mRCC as indication approved and physician criterium

Trial Locations (1)

Unknown

Pfizer Investigational Site, Panama City

Sponsors

Lead Sponsor

All Listed Sponsors

lead

Pfizer

INDUSTRY